Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

For adults (age 18 and older):

• You are being evaluated or treated for cancer at the NIH Clinical Center or a participating site
• You have been newly diagnosed with cancer and have not yet started treatment, OR your cancer has come back or is getting worse despite treatment, OR you are currently being treated and your response to treatment has not yet been checked
• You have had a partial response to treatment or your cancer has been stable (not growing)
• You are willing and able to sign a consent form agreeing to have your tissue or fluid samples used for research
• At the NIH Clinical Center only: You are 18 or older and have a confirmed hereditary cancer syndrome (such as Hereditary Breast and Ovarian Cancer) but have not yet developed an invasive cancer (confirm with trial site)
• At the NIH Clinical Center only: You have a blood cancer, including certain pre-cancerous blood conditions like MDS, and meet all other adult requirements (confirm with trial site)

For children (older than 2 months and under 18 years):

• You have been diagnosed with cancer (either a solid tumor or a blood cancer) confirmed by a lab test
• You are being treated at the NIH Clinical Center or a participating site
• You are already scheduled to have a medical procedure where tumor tissue, a needle biopsy sample, or bone marrow sample will be collected as part of your normal care
• You (where age-appropriate) and your parent or guardian are willing to agree to participate
• At the NIH Clinical Center only: You have a pediatric tumor that is generally non-cancerous but has a known risk of becoming cancerous, such as neurofibromatosis (confirm with trial site)

Who may not be able to join:

For adults:

• You have a cancer-like condition or blood disorder such as systemic mastocytosis, Langerhans cell histiocytosis, hypereosinophilic syndrome, lymphomatoid granulomatosis, or MGUS (a condition where abnormal proteins are found in the blood)
• You currently have an invasive fungal infection
• You have an active, uncontrolled infection, or have not fully recovered from one — specifically, all antibiotic, antifungal, or antiviral treatment for the infection must have been finished at least 7 days before sample collection, and you must have had no return of fever or infection symptoms for at least 7 days after finishing that treatment (note: taking antibiotics or antivirals to prevent infection, rather than treat one, does not disqualify you)
• You have HIV, active or chronic hepatitis B or C, or a known history of hepatitis B or C
• You have been diagnosed with active Hepatitis A (note: having a past immunity to Hepatitis A does not disqualify you)
• Only a blood sample is planned, and your cancer is a solid tumor or blood cancer that is currently showing a partial or stable response to treatment — blood samples will not be collected in this situation
• Only a blood sample is planned, and it would be collected between doses within a single treatment cycle
• You have a benign (non-cancerous) tumor, carcinoma in situ (very early-stage, non-invasive abnormal cells), or your cancer has completely responded to treatment

For children:

• You currently have an invasive fungal infection
• You have an active, uncontrolled infection or have not fully recovered — all antibiotics must have been finished at least 7 days before sample collection, and you must have had no return of fever or symptoms for at least 7 days after finishing treatment; you must not currently have a fever of unknown cause (note: taking antibiotics to prevent infection does not disqualify you)
• You have HIV, active or chronic hepatitis B or C, or a known history of hepatitis B or C
• You have been diagnosed with active Hepatitis A (note: having past immunity to Hepatitis A does not disqualify you)
• You have a benign (non-cancerous) tumor, carcinoma in situ, or your cancer has completely responded to treatment based on imaging
• Only a blood sample is planned and your cancer is showing a partial or stable response to treatment, or the sample would be collected between doses within a single treatment cycle

Important: Always verify eligibility with the trial site directly before applying.